UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 15, 2015
Cynapsus Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| Canada | 001-37426 | 98-1226819 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
|
828 Richmond Street West, Toronto, Ontario, Canada (Address of principal executive offices) |
M6J 1C9 (Zip Code) |
Registrant’s telephone number, including area code: 416-703-2449
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 3.02 | Unregistered Sales of Equity Securities. |
From October 1, 2015 to December 15, 2015, Cynapsus Therapeutics Inc. (the “Company”) issued an aggregate of 122,840 common shares pursuant to the exercise of warrants, for aggregate cash consideration of Cdn$1,218,734. Such common shares were issued by the Company outside the United States to persons that are not “U.S. persons” (as both such terms are defined in Regulation S under the United States Securities Act of 1933, as amended (“Regulation S”)) in reliance upon Regulation S.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CYNAPSUS THERAPEUTICS INC. | |||
| Date: December 15, 2015 | By: | /s/ Andrew Williams | |
| Name: | Andrew Williams | ||
| Title: | Chief Operating Officer and Chief Financial Officer | ||